Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 6, 2003, Pages 647-654

  Vergara, M ^a   Vallve, M ^a   Gisbert, J P ^b   Calvet, X ^a,c  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Unitat de Malalties Digestives   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ERADICATION THERAPY; HEALTH CARE ORGANIZATION; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0141650537     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01746.x     Document Type: Article

References (56)

1. van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-6.
2. Thiede C, Morgner A, Alpen B, et al. What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? Gastroenterology 1997; 113: S61-S64.
3. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
4. McColl K, Murray L, El Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869-74.
5. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J 2000; 321: 659-64.
6. Gisbert JP, Calvet X, Gomollon F, et al. Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000; 114: 185-95.
7. Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol 1999; 13: 213-7.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection -the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
9. Thomson AB. Are the orally administered proton pump inhibitors equivalent? a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93.
10. Richter JE, Kahrilas PJ, Johanson J. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
11. Holtmann G, Bytzer P, Metz M. et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85.
12. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
13. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41: 735-9.
14. Spinzi GC, Bierti L, Bortoli A, et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 433-8.
15. Catalano F, Privitera U, Branciforte G, et al. Omeprazole versus two different doses of lansoprazole in triple therapy on Helicobacter pylori positive duodenal ulcer. Gut 1997; 39: A32 (Abstract).
16. Inaba T, Mizuno M, Kawai K, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002; 17: 748-53.
17. Vakil N, Kovacs T, Ignatowitz W, Hahne W, Barth J. Presence or absence of peptic ulcer disease does not affect H.pylori eradication rates with rabeprazole-based triple therapy. Gut 2002; 51: A93 (Abstract).
18. Murakami K, Nasu M, Fujioka T, et al. Evaluation of the eradication effect for Helicobacter pylori against clarithromycin sensitive strains and clarithromycin resistant strains in triple therapy with rabeprazole, amoxycillin and clarithromycin: randomized comparison with triple therapy using lansoprazole. Gut 2002: 51 A99 (Abstract).
19. Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45: 77-82.
20. Bayerdorffer E, Ebert S, Kitsch C, et al. Effective one-week triple therapy with esomeprazole, clarithromycin and metronidazole for eradication of Helicobacter pylori in the absence of antimicrobial resistance: a prospective randomized trial. Gut 2002; 51: A101 (Abstract).
21. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13: 1457-65.
22. Veldhuyzen van Zanten SJ, Lauritsen K, Delchier JC, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 1605-11.
23. Dojo M, Azuma T, Saito T, et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001; 33: 671-5.
24. Aydin A, Gunsar F, Yilmaz M, et al. Omeprazole, lansoprazole or ranitidine bismuto citrate in combination with amoxycillin plus clarithromycin in Helicobacter pylori eradication. Gut 1998; 43: A307 (Abstract).
25. Kositchaiwat C, Ovartlampom B. One week triple therapy with low dose rabeprazole in eradicating Helicobacter pylori; a preliminary report. J Gastroenterol Hepatol 2002; 17: A816 (Abstract).
26. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981; 2: 31-49.
27. Clarke M, Oxman AD. Cochrane Reviewers Handbook 4.0. Oxford: The Cochrane Collaboration, 2001.
28. Catalano F, Branciforte G, Catanzaro R. et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter 1999; 4: 178-84.
29. Caroli A, Monica F, Sperti C, et al. Lansoprazole versus omeprazole in double therapy with amoxycillin for cure of Helicobacter pylori infection. Gastroenterology 1997: 112: A83 (Abstract).
30. Miwa H, Nagahara A, Sato K, et al. Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999; 14: 317-21.
31. Rinaldi V, Zullo A, Diana F, et al. Lansoprazole/amoxycillin versus omeprazole/amoxycillin in Helicobacter pylori eradication. Gastroenterology 1997; 112: A269 (Abstract).
32. Battaglia G, Di Mario F, Leandro G, et al. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. Helicobacter 1998; 3: 115-9.
33. Camarota G, Tursi A, Cannizaro A, et al. Three-day therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection. Cut 1998; 43: A92 (Abstract).
34. Misiewicz JJ, Harris AW, Bardhan KD, Levi S. One-week low dose Helicobacter pylori eradication therapy heals 90% of duodenal ulcers. Gut 1996: 39: A34 (Abstract).
35. Harris AW, Misiewicz JJ, Bardhan KD, et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Aliment Pharmacol Ther 1998; 12: 741-5.
36. Dominguez-Martin A, Domínguez-Muñoz A, Muñoz S, et al. Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxycillin versus omeprazole plus clarithromycin and amoxycillin for Helicobacter eradication. Gastroenterology 1998; 114: A107 (Abstract).
37. Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection. Am J Gastroenterol 1997; 92: 1949-50.
38. Wong BC, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1959-65.
39. Miyoshi M, Mizuno M, Ishiki K, et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-8.
40. Veldhuyzen van Zanten SJ, Hussein-Babba FA, Lee JSM. Effectiveness of either esomeprazole or omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori infection. Gut 2002; 51: A96 (Abstract).
41. Vakil N, Schwartz HJ, Lanza FL, et al. A prospective, controlled, randomized trial of 3-, 7- and 10-day rabeprazole-based triple therapy for Helicobacter pylori eradication in the USA. Gastroenterology 2002; 122: A65 (Abstract).
42. Hawkey CJ, Atherton JC, Treichel HC, et al. Rabeprazole vs. omeprazole in 7-day triple therapy H. pylori eradication regimens for peptic ulcer. Gastroenterology 2000; 120: A581 (Abstract).
43. Bhasin DK, Sharma BC, Shina SK, Ray P, Vaiphei K, Pathak CM. Comparison of multidrug regiments for eradication of Helicobacter pylori. Gastroenterology 1999; 116: A123 (Abstract).
44. Jonas C, DeReuck M, Otero J, Van Gossum M, Deltenza M. Low dose, one-week triple therapies for Helicobacter pylori. A randomized study. Gastroenterology 1996; 110: A145 (Abstract).
45. Pilotto A, Dal Bo N, Franceschi M, et al. Comparison of three proton pump inhibitors (PPI) in combination with amoxycillin and metronidazole for one week to cure Helicobacter pylori infection in the elderly. Gut 1998; 43: A91 (Abstract).
46. Torii AM, Ubukata HF, Soeda SF, et al. Effectiveness of rabeprazole, amoxycillin and clarithromycin in eradicating Helicobacter pylori: comparison of rabeprazole versus lansoprazole, omeprazole, and famotidine. Gastroenterology 1999; 116: A335 (Abstract).
47. Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 458-61.
48. Alarcon T, Domingo D, Sanchez I, et al. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1998; 17: 275-7.
49. Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998; 27: S63-9.
50. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
51. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
52. Ohning GV, Barbuti RC, Kovacs TO, et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701-8.
53. Williams MP, Blanshard C, Millson C, et al. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000; 14: 691-9.
54. Pommerien W, Schultze V, Braden B. et al. Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 303-8.
55. Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11: 323-9.
56. Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149-56.